Compare Adaptive Biotechnologies Corp (ADPT) vs Adecoagro SA (AGRO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Adecoagro SA — how do they compare? Adaptive Biotechnologies Corp trades at $25.05 (market cap $4.04B), while Adecoagro SA trades at $9.32 (market cap $1.36B). The key difference: Adaptive Biotechnologies Corp is far larger — about 3× Adecoagro SA's market cap, and Adecoagro SA pays a 3.15% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | AGRO | |
|---|---|---|
Market Cap | $4.04B | $1.36B |
Sector | Health | Technology |
52-Week High | $25.45 | $15.25 |
52-Week Low | $12.30 | $7.13 |
Enterprise Value | $4.10B | $3.39B |
Dividend Yield | — | 3.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $25.45, up 2.09% today, near its 52-week high. The stock shows bullish technical signals with support at $25 and resistance at $26. Revenue growth accelerated to $277M in 2025, though net losses persist. Recent news highlights a strategic separation of its MRD and Immune Medicine businesses, aiming to unlock value.
Outlook is cautiously optimistic with 65% analyst buy ratings and a $25.50 price target. Key opportunities include MRD segment profitability and separation benefits, while risks involve sustained losses, competitive pressures, and execution challenges in the business split.
AGRO is trading at $9.01, down 6.73% today, with a bearish technical outlook despite attractive valuation ratios (P/S: 0.71, P/B: 0.77). The company reported mixed quarterly results with one beat and three misses in recent quarters, while showing improved adjusted EBITDA of $172.5 million in Q2 2026. Recent expansion via the Caarapó mill acquisition and Profertil integration provides growth catalysts amid commodity volatility.
The stock presents a value opportunity with below-market multiples but faces execution risks from negative earnings momentum and high leverage. Analyst consensus is mixed with 37.5% buy ratings and a $12.12 price target, suggesting 35% upside potential if operational improvements materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Adecoagro SA
Adecoagro is a South American agricultural company. It operates a diversified business including farming crops, rice, and dairy, as well as producing sugar, ethanol, and renewable energy from its industrial facilities.
Read more on AGRO →
